Dow Up2.00% Nasdaq Up1.66%

Inovio Pharmaceuticals, Inc. (INO)

6.27 Up 0.08(1.29%) Feb 12, 4:00PM EST
|After Hours : 6.26 Down 0.01 (0.16%) Feb 12, 7:03PM EST
ProfileGet Profile for:
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Suite 100
Plymouth Meeting, PA 19462
United States - Map
Phone: 267-440-4200
Fax: 267-440-4242

Index Membership:N/A
Full Time Employees:106

Business Summary 

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company’s SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, influenza, and Ebola. Inovio Pharmaceuticals, Inc. has collaborative development agreement with GeneOne Life Sciences to co-develop an Ebola vaccine through phase I clinical trials. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Inovio Pharmaceuticals, Inc.

Corporate Governance 
Inovio Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 3; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. J. Joseph Kim Ph.D., 47
Chief Exec. Officer, Pres, Director and Member of Fin. Committee
Mr. Peter D. Kies , 53
Chief Financial Officer
Dr. Niranjan Y. Sardesai Ph.D., 48
Chief Operating Officer
Dr. Mark L. Bagarazzi M.D., 55
Chief Medical Officer
Mr. Bernie Hertel ,
VP of Investor Relations and Communications
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders